Compare Emerson Electric Co. (EMR) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Emerson Electric Co. vs Repligen Corporation Common Stock — how do they compare? Emerson Electric Co. trades at $160.84 (market cap $91.20B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Emerson Electric Co. is far larger — about 8.2× Repligen Corporation Common Stock's market cap, and Emerson Electric Co. pays a 1.36% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Emerson Electric Co. for 81 Days and Repligen Corporation Common Stock for 0 Days on average.
| EMR | RGEN | |
|---|---|---|
Market Cap | $91.20B | $11.14B |
Volume | 2,131,741 | 1,259,263 |
Sector | Industrials | Health |
52-Week High | $164.38 | $194.57 |
52-Week Low | $123.30 | $102.87 |
Typical Hold Time | 81 Days | 0 Days |
Enterprise Value | $102.28B | $11.02B |
Dividend Yield | 1.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Emerson Electric (EMR) trades at $163.50, up 0.64% today, with a bullish technical outlook and strong earnings momentum after beating estimates for three consecutive quarters. The stock shows robust profitability with a 13.83% net income margin and trades near the consensus price target of $165.90. Recent cash flow trends indicate improving operational performance, while analyst sentiment remains positive with 53% buy ratings.
EMR offers steady growth potential driven by earnings consistency and favorable analyst targets, but risks include elevated valuation multiples and debt level fluctuations. The stock's proximity to resistance at $164 suggests near-term consolidation may occur, yet fundamental strength supports a constructive long-term outlook for investors seeking industrial sector exposure.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
